A systematic review of 26 randomized controlled trials highlights that Eli Lilly’s experimental drug retatrutide achieves the greatest weight loss among GLP-1 receptor agonists and co-agonists, with a 22% reduction in body weight after 48 weeks. The review, conducted by McGill University researchers, also evaluated tirzepatide (18% weight loss after 72 weeks) and semaglutide (14% weight loss after 68 weeks), both commercially available. While all GLP-1 drugs reduced BMI, blood pressure, and waist circumference with a similar safety profile, gastrointestinal side effects were common, leading to treatment discontinuation in up to 26% of patients. The findings reinforce the potential need for chronic use of GLP-1 therapies for sustained efficacy. With retatrutide’s promise, could it redefine obesity treatment and shift the weight-loss paradigm?
Keep Reading
Add A Comment